Uffe Høgh Olesen
Currently, we are exploring the use of ablative fractional laser to facilitate localised, topical treatment with systemic anticancer drugs. This allows for more efficient treatment of skin cancer with reduced side-effects. Specifically, we aim to use the very promising systemically applied drugs, hedgehog inhibitors, for localised treatment of basal cell carcinomas, the most common cancer in humans. The project combines preclinical and clinical research, which is conducted in collaboration with the Technical University of Denmark, Harvard Medical School and University of Copenhagen. The research effort is supported by The Danish Council for Independent Research - Medical Sciences and The Research Foundation for Healthcare Research of the Capital Region of Denmark.